Risk-Reducing Mastectomy for BRCA Gene Mutation Carriers
نویسندگان
چکیده
منابع مشابه
Risk-reducing salpingo-oophorectomy for BRCA mutation carriers.
It has been twenty years since the region of the BRCA1mutationwas identified on chromosome 17q. There are now over 3000 risk reducing salpingo-oophorectomy (RRSO) cases reported and an estimated 150 cases describing unsuspected cancers of the ovaries and tubes or in situ lesions. Connor et al. in their current study add to the literature on RRSO outcomes [1]. They report on 345 cases of RRSO in...
متن کاملTime to decide about risk-reducing mastectomy: A case series of BRCA1/2 gene mutation carriers
BACKGROUND The purpose of this research was to explore women's decision-making experiences related to the option of risk-reducing mastectomy (RM), using a case series of three women who are carriers of a BRCA1/2 gene mutation. METHODS Data was collected in a pilot study that assessed the response of women to an information booklet about RM and decision-making support strategies. A detailed an...
متن کاملExperience with Bilateral Risk-Reducing Mastectomy for an Unaffected BRCA Mutation Carrier
Women with BRCA1/2 mutations have a high risk of breast cancer and may opt for risk-reducing mastectomy (RRM). We report a 38-year-old Japanese woman who was diagnosed as a BRCA2 mutation carrier. She underwent prophylactic bilateral skin-sparing mastectomy (SSM) with excision of the nipple and preservation of the areola skin. It is unclear whether a bilateral RRM leads to better survival compa...
متن کاملRisk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.
OBJECTIVE The objective of this study was to review the role of bilateral salpingo-oophorectomy in BRCA mutation (mBRCA) carriers and alternative interventions in risk reduction of ovarian cancer (OC). MATERIALS AND METHODS A systematic review using PubMed, MEDLINE, EMBASE, and the Cochrane library was conducted to identify studies of different strategies to prevent OC in mBRCA carriers, incl...
متن کاملContralateral risk reducing mastectomy in Non-BRCA-Mutated patients
The use of contralateral risk reducing mastectomy (CRRM) is indicated in women affected by breast cancer, who are at high risk of developing a contralateral breast cancer, particularly women with genetic mutation of BRCA1, BRCA2 and P53. However we should consider that the genes described above account for only 20-30% of the excess familiar risk. What is contralaterally indicated when genetic a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Surgical Oncology
سال: 2015
ISSN: 1068-9265,1534-4681
DOI: 10.1245/s10434-015-4537-9